Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q1 FY26 Earnings Presentation
13 slides from Glenmark Pharmaceuticals's earnings presentation, Aug 14, 2025
Slide 1: Investor Presentation: Q1 FY26
Investor Presentation: Q1 FY26 14 August 2025
Slide 2: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 3: Q1 FY26 Summary
Q1 FY26 Summary Consolidated • Consolidated Revenue of Rs. 32,644 Mn Revenue • YoY growth of 0.6% “In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAG
Slide 4: Consolidated Revenues – Q1 FY26
Consolidated Revenues – Q1 FY26 First Quarter ended June 30 Fourth Quarter ended March 31 YoY Growth QoQ Growth Rs Mn FY 2025-26 FY 2024-25 FY 2024-25 (%) (%) India 12,399 11,962 3.7% 9,430 31.5% North America 7,780 7,808 -0.4% 7,146 8.9% Europe 6,678 6,957 -4.0% 7,335 -9.0% Emerging Markets 1 5,721
Slide 5: P&L Highlights
P&L Highlights Rs. Mn Q1 FY26 Q1 FY25 %YoY Q4 FY25 %QoQ Revenues from Operations 32,644 32,442 0.6% 32,562 0.3% Gross Margin 22,489 21,341 21,673 Gross Margin (%) 68.9% 65.8% 66.6% EBITDA 5,805 5,882 -1.3% 5,607 3.5% EBITDA Margin (%) 17.8% 18.1% 17.2% Other Income (exp) 264 315 116 Exceptional gain
Slide 6: India
Q1 FY26 38% India Significant outperformance Launched TEVIMBRA® compared to IPM: >15% (Tislelizumab) and growth in Q1 FY26 BRUKINSA® (Zanubrutinib) Revenue (INR million) ▪ Sustained higher growth and continuous improvement in market shares in the Cardiac, Dermatology and Respiratory therapeutic area
Slide 7: North America
Q1 FY26 38% North America 3 products launched in Q1 52 ANDAs pending for including Mixed approval, including 24 Para Amphetamines IR Tablets IV applications (gx Adderall®) ▪ USD 91 Mn sales with QoQ growth of 8.9% Revenue (INR million) ▪ Launched 3 products: QoQ: 8.9% YoY: -0.4% o Mixed Amphetamines
Slide 8: Europe
Q1 FY26 38% Europe Branded Respiratory Recorded >25% CAGR over portfolio continues strong the last 3 years momentum Revenue (INR million) ▪ Expecting overall region to record double-digit growth in FY26. YoY: -4.0% QoQ: -9.0% ▪ Slowdown during the quarter was offset by branded business growth: 7,335
Slide 9: Emerging Markets (EM)
Q1 FY26 38% Emerging Markets (EM)1 Anticipate double-digit Recorded ~10% CAGR over growth in FY26 on a the last three years constant currency basis Revenue (INR million) ▪ Russia: secondary sales recorded growth of 21% and 11% in Q1 FY26 and YoY: 0.2% MAT June 2025. Glenmark ranked 9th in the Dermat
Slide 10: Creating Global Brands
Creating Global Brands RYALTRIS® ▪ As of June 2025, marketing applications for RYALTRIS® have been submitted in more than 90 countries across the world and the product has been commercialized in >45 markets. Further, it is expected to be launched in 10-12 additional markets over the next few quarter
Slide 11: Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours
Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours PRE- GLOBAL ASSET DESCRIPTION INDICATION DISCOVERY PHASE 1 PHASE 2 PHASE 3 CLINICAL RIGHTS CD38 x BCMA x CD3 Multiple ISB 2001 TREAT trispecific T- Cell Engager Myeloma IL-1RAP antagonist Hidradenitis ISB 880 /
Slide 12: IGI - Key updates
IGI - Key updates ▪ During the quarter, IGI presented promising full dose-escalation results from its Phase 1 TRIgnite-1 study of ISB 2001 o Demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% across seven active dose level
Slide 13: Thank You
G Glenmark Thank You
Glenmark Pharmaceuticals — Q1 FY26 Earnings Presentation on 6ix